Pfizer protects $6.4bn heart disease blockbuster from generics, for now
Pfizer has successfully warded off three drug manufacturers from placing generics referencing Vyndamax (tafamidis) on the US market, though the …
Post
-
-
Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact
Eli Lilly is locking down on its rapid expansion strategy with a second deal this week – joining forces with …
-
The strategic investments expanding CDMO capabilities for HPAPIs and ADCs
As oncology pipelines continue to expand and targeted therapies become more sophisticated, contract development and manufacturing organisations (CDMOs) must invest …
-
Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies
A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars being spent …
-
Arcera and Fosun sign MoU for neuroscience innovation
Arcera Life Sciences and Fosun Pharma have signed a memorandum of understanding (MoU) for a strategic long-term collaboration in licensing, …
-
Rocket to sell PRV for $180m to advance gene therapy pipeline
Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease priority review voucher (PRV) for $180m to advance …
-
Merck KGaA and Remepy join forces to develop combo drug-digital therapies
Merck KGaA has inked a collaboration deal with Israeli-US startup, Remepy, to explore the therapeutic potential of combination drug and …
-
Seaport and Hemab target $180m IPOs as biotech listings accumulate
Seaport Therapeutics and Hemab Therapeutics have both outlined pricings for their respective initial public offerings (IPOs), adding to an already …
-
BioMarin acquires Amicus Therapeutics for $4.8bn
BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal …
-
FDA approves AstraZeneca’s Saphnelo for SLE
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for the subcutaneous self-administration of Saphnelo (anifrolumab-fnia) using …
-
Early detection of bowel Cancer in the UK represents success of screening program
Bowel cancer, also known as colorectal cancer, is the second most lethal cancer after lung cancer, with the highest incidence …
-
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics
Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire cancer specialist Ajax …
-
Pharma Meets AI Conference 2026: AI in pharma begins delivering measurable ROI
At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions around AI governance highlighted a growing shift …
-
Pharma Meets AI Conference 2026: AI governance shifts to embedded practice
At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions around AI governance highlighted a clear shift …
-
ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Phase III data for Aicuris’s pritelivir, …
